Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Prepaid Assets: 2014-2024

Historic Prepaid Assets for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $23.9 million.

  • ImmunityBio's Prepaid Assets rose 27.11% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 27.11%. This contributed to the annual value of $23.9 million for FY2024, which is 6.84% down from last year.
  • ImmunityBio's Prepaid Assets amounted to $23.9 million in FY2024, which was down 6.84% from $25.6 million recorded in FY2023.
  • ImmunityBio's Prepaid Assets' 5-year high stood at $31.5 million during FY2022, with a 5-year trough of $13.6 million in FY2020.
  • Moreover, its 3-year median value for Prepaid Assets was $25.6 million (2023), whereas its average is $27.0 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first soared by 232.50% in 2020, then declined by 18.73% in 2023.
  • Over the past 5 years, ImmunityBio's Prepaid Assets (Yearly) stood at $13.6 million in 2020, then increased by 16.48% to $15.9 million in 2021, then spiked by 98.16% to $31.5 million in 2022, then declined by 18.73% to $25.6 million in 2023, then decreased by 6.84% to $23.9 million in 2024.